Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2024 | $9.00 | Overweight | Piper Sandler |
| 8/9/2021 | $13.50 | Buy | Roth Capital |
LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, at 2:15 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To request a 1x1 meeting with management, please contact your Needham representative. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments f
- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2025 is positioned to be a transformational year for Unicycive, with the near-term potential for
LOS ALTOS, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the publication of preclinical data describing the benefits of combination treatment of oxylanthanum carbonate (OLC) and tenapanor on phosphate management in the American Society of Nephrology (ASN) journal, Kidney360. The publication, entitled "Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rats," examines the potential synergistic benefits of a combination of OLC, a phosphate binder, with tenapanor, a sodium/hydrogen exchanger 3 (NHE3) inhibito
4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
S-8 - Unicycive Therapeutics, Inc. (0001766140) (Filer)
8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
10-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company's Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara's leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive's future growth. "We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadersh
LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will have responsibility for Unicycive's corporate and commercial strategy and business development activities. Doug has spent the majority of his career focused on drugs for treatment of kidney diseases"With a career spent in heal
Piper Sandler initiated coverage of Unicycive Therapeutics with a rating of Overweight and set a new price target of $9.00
Roth Capital initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $13.50
SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Commercial planning in preparation for anticipated commercial launch of OLC in late 2025 LOS ALTOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2025 is positioned to be a transformational year for Unicycive, with the near-term potential for
– OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025– – Commercial Planning in Progress for 2025 Launch – – Late Breaker Poster Presentation on OLC at ASN Kidney Week – – Successful Completion of UNI-494 Phase 1 Trial – LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2024, and provided a business update. "We are pleased with the
– On Track to Submit OLC New Drug Application (NDA) by End of August 2024 – LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended June 30, 2024, and provided a business update. "Achieving successful results from our oxylanthanum carbonate (OLC) pivotal trial was a significant milestone for the company and brings us one step closer to becoming a commercial organization," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "Impor